Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLPH NASDAQ:BPTSY NASDAQ:CERO NASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/ABPTSYBiophytis$0.25$0.25$0.00▼$2.08$586K2.461,154 shs4 shsCEROCERo Therapeutics$0.01-11.5%$0.01$0.01▼$8.90$510K0.13688,866 shs1.41 million shsPTIXAtrinsic$0.22$0.41$0.14▼$6.20$390K1.0131,806 shs22 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%BPTSYBiophytis0.00%0.00%0.00%0.00%-86.15%CEROCERo Therapeutics-5.66%-9.09%+23.46%-70.85%-99.88%PTIXAtrinsic0.00%-17.17%-40.09%-73.38%-93.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/ABPTSYBiophytis$0.25$0.25$0.00▼$2.08$586K2.461,154 shs4 shsCEROCERo Therapeutics$0.01-11.5%$0.01$0.01▼$8.90$510K0.13688,866 shs1.41 million shsPTIXAtrinsic$0.22$0.41$0.14▼$6.20$390K1.0131,806 shs22 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%BPTSYBiophytis0.00%0.00%0.00%0.00%-86.15%CEROCERo Therapeutics-5.66%-9.09%+23.46%-70.85%-99.88%PTIXAtrinsic0.00%-17.17%-40.09%-73.38%-93.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/ACEROCERo Therapeutics 1.67Reduce$30.00299,900.00% UpsidePTIXAtrinsic 1.00SellN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/ACEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/AN/AN/AN/AN/AN/AN/ABPTSYBiophytis-$18.43MN/AN/AN/AN/AN/AN/AN/AN/ACEROCERo Therapeutics-$8.30M-$71.01N/AN/AN/AN/AN/A-209.40%9/2/2026 (Estimated)PTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%8/18/2026 (Estimated)Latest BLPH, BPTSY, CERO, and PTIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026N/APTIXAtrinsic-$4.48N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/AN/AN/ABPTSYBiophytisN/A0.41N/ACEROCERo TherapeuticsN/A0.560.56PTIXAtrinsicN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%BPTSYBiophytis0.05%CEROCERo Therapeutics29.64%PTIXAtrinsic7.97%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%BPTSYBiophytis3.70%CEROCERo Therapeutics0.36%PTIXAtrinsic8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataBPTSYBiophytis302.35 million338,000N/ACEROCERo Therapeutics845.11 million1.05 millionN/APTIXAtrinsic21.81 million1.78 millionNot OptionableBLPH, BPTSY, CERO, and PTIX HeadlinesRecent News About These CompaniesProtagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent ModelJune 30, 2026 | accessnewswire.comAProtagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations PartnerMay 19, 2026 | accessnewswire.comAProtagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114April 23, 2026 | accessnewswire.comAProtagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114March 17, 2026 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?March 4, 2026 | defenseworld.netDResults from Phase 1 Multiple-Dose Study of PT00114December 9, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeNovember 27, 2025 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?November 22, 2025 | defenseworld.netDProtagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD StudyNovember 13, 2025 | accessnewswire.comAProtagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq ComplianceAugust 22, 2025 | accessnewswire.comAProtagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood DisordersAugust 21, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | prismmediawire.comPProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21, 2025 | thepharmaletter.comTProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21, 2025 | accessnewswire.comAProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLPH, BPTSY, CERO, and PTIX Company DescriptionsBellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Biophytis NASDAQ:BPTSY$0.25 0.00 (0.00%) As of 07/24/2026Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.CERo Therapeutics NASDAQ:CERO$0.01 0.00 (-11.50%) As of 07/24/2026 03:59 PM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Atrinsic NASDAQ:PTIX$0.22 0.00 (0.00%) As of 07/24/2026Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
